209 related articles for article (PubMed ID: 36932129)
1. Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma.
Simon SM
Nat Rev Cancer; 2023 May; 23(5):335-346. PubMed ID: 36932129
[TBL] [Abstract][Full Text] [Related]
2. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
[TBL] [Abstract][Full Text] [Related]
4. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features of Two Extremely Rare Hepatocellular Carcinoma Variants: a Brief Review of Fibrolamellar and Scirrhous Hepatocellular Carcinoma.
Samdanci ET; Akatli AN; Soylu NK
J Gastrointest Cancer; 2020 Dec; 51(4):1187-1192. PubMed ID: 32860202
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
7. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors.
Ward SC; Waxman S
Semin Liver Dis; 2011 Feb; 31(1):61-70. PubMed ID: 21344351
[TBL] [Abstract][Full Text] [Related]
8. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
9. Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma.
Levin SN; Tomasini MD; Knox J; Shirani M; Shebl B; Requena D; Clark J; Heissel S; Alwaseem H; Surjan R; Lahasky R; Molina H; Torbenson MS; Lyons B; Migler RD; Coffino P; Simon SM
Sci Adv; 2023 Jun; 9(25):eadg7038. PubMed ID: 37343102
[TBL] [Abstract][Full Text] [Related]
10. Fibrolamellar Carcinoma: What Is New and Why It Matters.
Graham RP
Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
[TBL] [Abstract][Full Text] [Related]
11. Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas.
Wege H; Schulze K; von Felden J; Calderaro J; Reig M;
Eur J Med Genet; 2021 Nov; 64(11):104313. PubMed ID: 34418585
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas.
Vivekanandan P; Torbenson M
Mod Pathol; 2008 Jun; 21(6):670-5. PubMed ID: 18264082
[TBL] [Abstract][Full Text] [Related]
13. Human liver organoids for disease modeling of fibrolamellar carcinoma.
Narayan NJC; Requena D; Lalazar G; Ramos-Espiritu L; Ng D; Levin S; Shebl B; Wang R; Hammond WJ; Saltsman JA; Gehart H; Torbenson MS; Clevers H; LaQuaglia MP; Simon SM
Stem Cell Reports; 2022 Aug; 17(8):1874-1888. PubMed ID: 35803261
[TBL] [Abstract][Full Text] [Related]
14. [Surgical therapy of hepatic fibrolamellar carcinoma].
Meriggi F; Forni E
Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
[TBL] [Abstract][Full Text] [Related]
15. The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients.
Darcy DG; Chiaroni-Clarke R; Murphy JM; Honeyman JN; Bhanot U; LaQuaglia MP; Simon SM
Oncotarget; 2015 Jan; 6(2):755-70. PubMed ID: 25605237
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization.
Wilkens L; Bredt M; Flemming P; Kubicka S; Klempnauer J; Kreipe H
Am J Clin Pathol; 2000 Dec; 114(6):867-74. PubMed ID: 11338475
[TBL] [Abstract][Full Text] [Related]
17. Fibrolamellar hepatocellular carcinoma at a tertiary centre in South Africa: a case series.
Bhaijee F; Locketz ML; Krige JE
S Afr J Surg; 2009 Nov; 47(4):108-11. PubMed ID: 20141066
[TBL] [Abstract][Full Text] [Related]
18. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
Kim J; Kim Y; Lee B
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
[TBL] [Abstract][Full Text] [Related]
19. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.
Dinh TA; Vitucci EC; Wauthier E; Graham RP; Pitman WA; Oikawa T; Chen M; Silva GO; Greene KG; Torbenson MS; Reid LM; Sethupathy P
Sci Rep; 2017 Mar; 7():44653. PubMed ID: 28304380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
